Zhifei Bio-products secures patent for H. pylori vaccine

Chongqing Zhifei Biological Products Co., Ltd. (Zhifei Bio-products), along with its wholly-owned subsidiaries Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., announced the acquisition of an invention patent certificate. The patent, titled "A method for preventing Helicobacter pylori infection, OMV vaccine and its preparation method," was granted by the National Intellectual Property Administration of the People's Republic of China.

The patent application date was March 14, 2024, and the authorization announcement date was September 30, 2025. The patent holders are Zhifei Bio-products, Zhifei Green Bamboo, and Zhifei Longcom.

This invention patent was obtained during the research and development process of the company's pipeline products and will be applied to relevant in-development products. While the acquisition of this patent certificate will not have a significant impact on its recent production and operations, it is beneficial for further improving the company's intellectual property protection system.

Furthermore, this patent acquisition allows the company to fully leverage its independent intellectual property advantages, promote technological innovation, and enhance its core competitiveness. The announcement was made by the Board of Directors of Chongqing Zhifei Biological Products Co., Ltd. on October 9, 2025.